Results 61 to 70 of about 50,558 (217)

From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences.
Heybet Kerem Polat, Yasin Turanlı, Nihat Kurt, Sefa Gözcü, Emre Tunçel, Hilal Bacanak, Eren Aytekin, Sedat Ünal   +7 more
wiley   +1 more source

Pharmacokinetic Evaluation of Rifabutin in Combination with Lopinavir-Ritonavir in Patients with HIV Infection and Active Tuberculosis

, 2020
Background. Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs.
• Rifabutin With Lopinavir-Ritonavir, Cid   +1 more
core  

Aspartic Protease Inhibition Induces Proteomic Remodeling in Paracoccidioides brasiliensis

PROTEOMICS, EarlyView.
ABSTRACT Paracoccidioidomycosis (PCM) is a major systemic mycosis in Latin America caused by Paracoccidioides brasiliensis, yet the contribution of aspartic proteases to fungal physiology and pathogenicity remains poorly understood. Here, we employed data‐independent acquisition (DIA)‐based quantitative proteomics to investigate the impact of pepstatin
Sarah Fernandes Lima, Wilson Dias Segura, Leonardo Brogliato de Moraes, Reinaldo Souza Oliveira, Pedro Henrique Corteletti Manfio, Alison Felipe Alencar Chaves, Wagner Luiz Batista   +6 more
wiley   +1 more source

Patent Landscape Report on Ritonavir. [PDF]

, 2019
This report is dedicated to Ritonavir - an antiretroviral drug used to treat HIV infection and AIDS. A major goal of the report is to highlight the technology timeline for Ritonavir from the first filing of this compound to the present filings.

core   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)

South African Journal of Science, 2015
Currently, the treatment of choice of HIV/AIDS in South Africa is the multidrug combination regimen known as HAART (highly active antiretroviral treatment).
Gbenga A. Adefolaju, Katherine E. Theron, Margot J. Hosie   +2 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

BMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider, Rika Wobser, Wolfgang Kühn, Dirk Wagner, Yakup Tanriver, Gerd Walz   +5 more
doaj   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source